Antibiotics in 30 Minutes or Less for Febrile Neutropenic Patients: A Quality Control Measure in a New Hospital

Abstract

Infections are the most common complication in patients receiving treatment for cancer with neutropenia being the primary risk factor for the development of an infection. In the neutropenic patient, bacteremia remains a significant cause of mortality. Although the literature reports that prompt empiric antibiotic therapy to prevent death caused by virulent organisms is the standard of care, the literature fails to identify what prompt antibiotic administration means. Door/fever-to-patient antibiotic delivery was evaluated as a quality control measure in a new children's hospital. Initially, door/fever-to-patient time was significantly delayed. Collaboration between pharmacy, hospital bed control, medical, and nursing staff resulted in many changes in practice by all groups. As a result, the goal for prompt antibiotic delivery of thirty minutes or less is now achievable.

Keywords

infections neutropenia antibiotic therapy quality measure

Get full access to this article

View all access options for this article.

References

Alcoser, P.W. (2004). Hematopoiesis and immune response. In N. E. Kline , D. S. Echtenkamp , R. Norville , & M. Silva (Eds.), The pediatric chemotherapy and biotherapy curriculum (pp. 7-10). Glenview, IL: Association of Pediatric Oncology Nurses.

Battleman, D.S. , Callahan, M. , & Thaler, H.T. (2002). Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Archives of Internal Medicine, 162, 682-688.

Cohen, M.A. (2006). Neutropenic fever. Journal of Emergency Medicine, 31, 227-228.

Christ-Crain, M. (2006). Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. American Journal of Respiratory and Critical Care Medicine. Retrieved October 17, 2007, from http://findarticles.com/p/articles/mi_qa4085/is_200607/ai_n17188886

Hann, I. , Viscoli, C. , Paesmans, M. , Gaya, H. , & Glauser, M. (1997). A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies . British Journal of Haematology, 99, 580-588.

Macartney, G. , Zvonar, R. , McDiarmid, S. , d'Entremont-Harris, B. , & Laplante, J. (2007). Risk stratification and febrile neutropenia: The Ottawa experience. Oncology Exchange, 6(3), 43-47.

McGarvey, R.N. & Harper, J.J. (1993). Pneumonia mortality reduction and quality improvement in a community hospital. Quality Review Bulletin, 19, 124-130.

Perrone, J. , Hollander, J.E. , & Datner, E.M. (2004). Emergency department evaluation of patients with fever and chemotherapy-induced neutropenia. Journal of Emergency Medicine, 27, 115-119.

Rackoff, W.R. , Gonin, R. , Robinson, C. , Kreissman, S.G. , & Breitfeld, P.P. (1996). Predicting the risk of bacteremia in children with fever and neutropenia. Journal of Clinical Oncology, 14, 919-924.

10.

Rolston, K.I. (2004). The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: Salient features and comments. Clinical Infectious Diseases, 39, S44-S48.

11.

Schimpff, S. , Satterlee, W. , Young, V.M. , & Serpick, A. (1971). Empiric therapy with carbenicillin and gentamycin for febrile patients with cancer and granulocytopenia. New England Journal of Medicine, 284, 1061-1065.

12.

Smiley, S. , Almyroudis, N. , & Segal, B.H. (2005). Epidemiology and management of opportunistic infections in immunocompromised patients with cancer. Abstracts in Hematology & Oncology, 8(3), 20-30.

13.

Whimbey, E. , Kiehn, T.E. , Brannon, P. , Blevins, A. , & Armstrong, D. (1987). Bacteremia and fungemia in patients with neoplastic disease. American Journal of Medicine, 82, 723-730.

14.

Wolff, L.J. , Altman, A.J. , Berkow, R.L. , Johnson, F.L. (2004). The management of fever and neutropenia. In A. J. Altman (Ed.), Supportive care of children with cancer: Current therapy and guidelines from the children's oncology group (3rd ed., pp. 25-38). Baltimore : Johns Hopkins University Press.